{"schema_version":"secwatch.filing_event.v1","accession":"0001654954-23-010378","form_type":"8-K","ticker":"ZIVO","cik":"0001101026","company_name":"Zivo Bioscience, Inc.","filed_at":"2023-08-09T23:59:59+00:00","discovered_at":"2026-05-14T18:03:33.141439+00:00","generated_at":"2026-06-11T21:21:13.997399+00:00","sec_items":["3.01"],"event_type":"regulatory","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Zivo Bioscience granted Nasdaq extension to Nov 20, 2023 to regain equity compliance","bullets":["Received deficiency notice on May 23, 2023 for stockholders' equity below $2.5M (Listing Rule 5550(b)).","Nasdaq Hearings Panel held on July 13, 2023; extension granted until November 20, 2023.","Extension conditioned on filing Form S-1 with SEC by October 5, 2023.","Company intends to regain compliance but delisting risk remains; potential adverse effect on capital access."],"urls":{"canonical":"https://secwatch.observer/filing/0001654954-23-010378","json":"https://secwatch.observer/filing/0001654954-23-010378.json","markdown":"https://secwatch.observer/filing/0001654954-23-010378.md","text":"https://secwatch.observer/filing/0001654954-23-010378.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1101026/000165495423010378/0001654954-23-010378-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1101026/000165495423010378/zivo_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-11T21:21:13.997399+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"b5e2623dbe13ba37c1786f458de3a563f7844b47","claim":"Zivo Bioscience, Inc. received a nasdaq extension granted notice regarding stockholders equity (rules 5550(b)).","evidence_excerpt":"August 4, 2023, the Company received a notification letter from the Nasdaq notifying the Company that the Panel has granted the Company’s request to provide an extension until November 20, 2023 (the “Exception Period”), to regain compliance with the Stockholders’ Equity Rule for continued listing on Nasdaq. The Panel further noted that the Exception Period for continued listing is subject to a filing of a registration statement on Form S-1 by the Company with the U.S. Securities and Exchange Commission (the “SEC”) on or before October 5, 2023. The Panel concluded that the Exception Period is","evidence_source":"SEC 8-K Item 3.01","evidence_url":"https://www.sec.gov/Archives/edgar/data/1101026/000165495423010378/0001654954-23-010378-index.htm","confidence":0.95,"family_label":"Listing & Compliance Notices","details":[{"label":"Exchange","value":"nasdaq"},{"label":"Notice","value":"extension granted"},{"label":"Deficiency","value":"stockholders equity"},{"label":"Rules","value":"5550(b)"}],"fact_type":"exchange_compliance_notice"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}